Drug discovery has doubled the flow of candidates, but approvals remain roughly flat. The constraint is development, not discovery.
In this episode, a16z General Partner, Jorge Conde talks with Formation Bio cofounder and CEO Ben Liu about building a modern pharma company around clinical execution. They discuss Formation Bio’s hub-and-spoke model for acquiring and advancing assets, how AI compresses trial timelines and costs, picking winners, regulatory strategy, and what it would take to move from about 50 approvals a year to many more. They also touch on global competition and why clinical proof still drives value in today’s market.\
Timecodes:
0:00 Introduction
0:38 Why Formation Bio? Origins and Mission
1:12 The Real Bottleneck: Clinical Development
4:56 Formation Bio’s Business Model
7:50 Picking Winners: The Art and Science of Drug Selection
11:54 First-in-Class vs. Best-in-Class Strategies
14:04 Overcoming Regulatory and Market Challenges
17:26 The Stakes: Can We Approve More Drugs?
19:07 How Formation Bio Cuts Cost and Time
21:43 AI’s Role in Drug Development
25:10 The Future: From 50 to 500 Drug Approvals?
35:18 Global Competition: The Rise of China
39:28 The Path Forward: Data, Regulation, and Access
41:47 Conclusion: Realizing the AI Revolution in Pharma
Resources:
Find Ben on X: https://x.com/BenjamineYLiu
Find Jorge on X: https://x.com/JorgeCondeBio
Stay Updated:
If you enjoyed this episode, be sure to like, subscribe, and share with your friends!
Find a16z on X: https://x.com/a16z
Find a16z on LinkedIn: https://www.linkedin.com/company/a16z
Listen to the Raising Health Podcast on Spotify: https://open.spotify.com/show/4fjb8YTzHDuPBgDXc3ElkR
Listen to the Raising Health Podcast Podcast on Apple Podcasts: https://podcasts.apple.com/us/podcast/raising-health/id1529318900
Follow our host: https://x.com/eriktorenberg
Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
